Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2022 | The role of alloSCT for R/R LBCL in the era of CAR-T therapy

Alberto Mussetti • 12 Dec 2022
ASH 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T

Alberto Mussetti, MD, Catalan Institute of Oncology, Barcelona, Spain, discusses the role of allogeneic stem cell transplantation (alloSCT) in patients with large B-cell lymphoma (LBCL), highlighting its value in patients who relapse or progress after CAR-T therapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

BMS: Consultancy; Takeda: Honoraria; Gilead: Research Funding; Jazz Pharmaceuticals: Consultancy.

More from Alberto Mussetti

The changing role of transplant in LBCL in the era of novel immunotherapies
2:10
The changing role of transplant in LBCL in the era of novel immunotherapies
Alberto Mussetti • 31 Mar 2025
The feasibility of alloSCT as consolidation therapy in R/R B-cell lymphoma exposed to bispecifics
1:36
The feasibility of alloSCT as consolidation therapy in R/R B-cell lymphoma exposed to bispecifics
Alberto Mussetti • 31 Mar 2025
Sequencing cellular therapy strategies in LBCL as the treatment landscape evolves
1:32
Sequencing cellular therapy strategies in LBCL as the treatment landscape evolves
Alberto Mussetti • 31 Mar 2025
Patterns of relapse after commercial use of anti-CD19 CAR-T in patients with R/R DLBCL
1:33
Patterns of relapse after commercial use of anti-CD19 CAR-T in patients with R/R DLBCL
Alberto Mussetti • 31 Mar 2025

Related Videos

Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026
Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals